解宝妈之急，补医生之缺。 文 ｜ 海若镜 封面来源 ｜ AI生成 今春，AI儿科医生是AI医疗圈的热门议题之一。 3月，北京儿童医院牵手百川智能，发布了国内首个儿科医学大模型，推出基层和专家两个版本"AI儿科医生"；4月，重医儿童医院联合左手医生，推 出"儿科AI家庭医生"，以及适配大模型应用的儿科循证知识库。 这两家顶级儿童医院迅速下场之外，还有多家医院正在应用AI儿科产品的路上。 现实中，儿科医生荒、儿童就医难等困境存在已久。因为儿童难以准确诉说病情，儿科又被称为"哑巴儿科"，医生仅能凭借有限沟通、查体等诊断病 情；儿童用药的品种有限，剂量也多靠医生酌情使用；再加上儿科又是"小全科"，培养一位优秀的儿科医生至少要八到十年。 借助AI大模型的"聪明大脑"，能否弥补儿医需求的巨大缺口？ 除了让AI服务医生、提高诊疗效率，医生调教后的AI能否直接服务患者？ AI儿科医生，有可能成为"医疗AI杀手级应用"吗？ AI儿科家医：解宝妈之急 一位健康的年轻女性成为妈妈后，往往要面对很多突如其来的医疗护理问题，如新生儿黄疸、肠胀气、湿疹、过敏等。 左手医生创始人兼CEO张超也表达了相似的看法，他归纳认为： "AI医生的竞 ...

" 一家三甲医院顶级专科和一家大厂，拥抱AI医疗的决心。 " 作者丨洪雨欣 编辑丨陈彩娴 "DeepSeek 一上线，行业有个声音是医生以后可能就没饭吃了。" 近期在一场公开活动中，上海交通大学医学院附属仁济医院（下简称"仁济医院"）副院长、泌尿科学科带头人薛蔚说道。这番话的另一面，是传统医疗机构对 新一代AI技术的价值重估。 2025 年开年，DeepSeek掀起了大模型领域的新走向，将行业落地的算力、算法门槛都大幅降低，使得AI与产业融合开始爆发，医疗就是其中的热门场景之 一。一时间，涌入了更多参赛者。有以腾讯、华为、京东、蚂蚁为代表的头部大厂，也有商汤、讯飞这样的科技巨头。 一方面，医疗行业需要AI：医患比例不平衡，使医院增效需求明显，分级诊疗的推进，也需要快速缩小各级机构诊断能力的差别。当前，先进模型在医学问答 测试中的部分表现已经超越全科医生水平。 另一方面，AI也需要医疗：AI医疗上限还远未到达，专才大模型得靠高质量医疗数据的调教，需要行业进一步合理利用数据、驱动创新发生。 在仁济医院，更早一步的探索已经显露出阶段性成果： 基于蚂蚁医疗大模型开发的仁济医院泌尿外科智能体（简称"RJUA智能体"）， ...

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks and a notable rise in the Hang Seng Healthcare ETF, reflecting positive market sentiment and growth potential in the healthcare sector [3][4]. Group 1: Market Performance - As of April 25, 2025, the HSHCI rose by 1.77%, with notable gains from stocks such as Yidu Tech (10.15%) and WeDoctor (7.05%) [3]. - The Hang Seng Healthcare ETF (513060) opened high and increased by 2.68%, marking its fifth consecutive rise, with a latest price of 0.50 yuan [3]. - Over the past week, the Hang Seng Healthcare ETF has accumulated an 8.50% increase [3]. Group 2: Liquidity and Trading Volume - The Hang Seng Healthcare ETF had a turnover rate of 1.57% during the trading session, with a transaction volume of 183 million yuan [3]. - The ETF's average daily trading volume over the past month was 2.072 billion yuan, ranking first among comparable funds [3]. Group 3: Policy and Industry Outlook - On April 24, 2025, the Ministry of Industry and Information Technology and six other departments issued a notice on the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)," aimed at enhancing the integration of AI and new information technologies within the pharmaceutical industry [3]. Group 4: Fund Performance and Metrics - The Hang Seng Healthcare ETF has seen a net asset growth of 715 million yuan over the past year, ranking in the top third among comparable funds [4]. - As of April 24, 2025, the ETF's net value increased by 41.16% over the past year, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio was reported at 1.34, indicating strong risk-adjusted returns [5]. Group 5: Valuation and Holdings - The latest price-to-earnings ratio (PE-TTM) for the HSHCI is 25.11, which is below 92.78% of the historical data over the past year, indicating a low valuation [5]. - The top ten weighted stocks in the HSHCI account for 57.54% of the index, with companies like BeiGene and WuXi Biologics being significant contributors [5].

智通财经4月25日电，早盘塞力医疗涨停，泓博医药、思创医惠涨超10%，创业慧康、朗玛信息、贝瑞 基因、卫宁健康、润达医疗等跟涨。消息面上，工信部等七部门关于印发《医药工业数智化转型实施方 案（2025—2030年）》提出，到2027年，医药工业数智化转型取得重要进展，以数智技术驱动的医药全 产业链竞争力和全生命周期质量管理水平显著提升。 AI医疗概念盘初活跃 塞力医疗涨停 ...

Core Insights - Innovation Medical Management Co., Ltd. reported a decline in operating performance for 2024 due to adjustments in medical insurance settlement policies, despite an increase in outpatient and inpatient volumes [1] - The company is focusing on enhancing supply chain management and developing self-funded medical projects to ensure stable operations [1] - Innovation Medical is investing in cutting-edge fields such as brain-computer interfaces and AI medical models, which have garnered significant attention from the capital market [1] Group 1: AI Medical Applications - In August 2024, Innovation Medical announced a strategic investment in Hangzhou Quanzhen Medical Technology Co., Ltd., acquiring a 20.5532% stake, recognizing the potential of AI in healthcare [2] - The AI medical model developed by Quanzhen Medical includes features like pre-consultation and electronic medical record writing, which enhance doctors' efficiency and diagnostic quality [2][3] - The AI model is expected to generate revenue of 4.4 million yuan in 2024, with a target of 40 million yuan in 2025, indicating strong growth potential [3] Group 2: Brain-Computer Interface Developments - Innovation Medical's investment in Bole Brain-Computer Technology Co., Ltd. has led to the development of a B-end product for rehabilitation training, currently undergoing clinical trials [4] - The C-end product, designed for enhancing upper limb function in stroke patients, is in mass production and expected to launch in 2025, marking a significant innovation in the market [4][5] - The C-end product aims to improve the quality of life for stroke patients, potentially saving them significant annual costs in care and hospital expenses [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2024 is in line with expectations, with total revenue of 1.834 billion yuan, a decrease of 5.35% year-on-year, and a net profit attributable to shareholders of 162.11 million yuan, down 26.75% year-on-year [8] - The company is focusing on six major medical fields and has seen strong performance in overseas markets, with overseas revenue reaching 1.098 billion yuan, an increase of 14.54% [8] - The introduction of innovative products, such as the i500 wet blood gas analyzer, has significantly improved testing efficiency and patient experience [8] - The company has adjusted its net profit forecasts for 2025-2026 due to short-term pressures from domestic procurement, with expected net profits of 203 million yuan and 254 million yuan respectively [8] Financial Summary - Total revenue forecast for 2024 is 1.834 billion yuan, with a projected increase to 2.020 billion yuan in 2025 and 2.226 billion yuan in 2026 [1][9] - The net profit attributable to shareholders is expected to decline to 162.11 million yuan in 2024, with a recovery to 202.85 million yuan in 2025 and 253.60 million yuan in 2026 [1][9] - The earnings per share (EPS) is projected to be 0.28 yuan in 2024, increasing to 0.35 yuan in 2025 and 0.44 yuan in 2026 [1][9] - The company maintains a high gross margin of 58.34% in Q1 2025, despite rising raw material costs [8]

| 序号 | 证券代码 | 证券简称 | 区目:张庆幅 [起始交易日期] 本年初 | | | --- | --- | --- | --- | --- | | | | | [截止交易日期] 最新收盘日 | | | | | | [单位] %] | | | 1 | 520500.OF | 华泰柏瑞恒生创新药ETF | | 33.6041 | | വ | 159570.OF | 汇添富国证港股通创新药ETF | | 29.8647 | | 3 | 517520.OF | 永赢中证沪深港黄金产业股票ETF | | 29.8213 | | ব | 159562.OF | 华夏中证沪深港黄金产业股票ETF | | 29.7344 | | 5 | 159567.OF | 银华国证港股通创新药ETF | | 29.4241 | | 6 | 159315.OF | 工银中证沪深港黄金产业股票ETF | | 29.3984 | | 7 | 159506.OF | 富国恒生港股通医疗保健ETF | | 29.2232 | | 8 | 513280.OF | 汇添富恒牛牛物科技ETF | | 29.0749 | | g | 15961 ...

Core Insights - The company reported a revenue of 12.196 billion yuan and a net profit of -0.357 billion yuan for the year 2024, with a significant improvement in operating cash flow [2] - As a leading third-party medical laboratory in China, the company serves over 22,000 medical institutions and offers more than 4,200 medical testing projects [2] - The company is leveraging market opportunities driven by the increasing demand for medical testing and pathology diagnosis in grassroots healthcare, projected to reach a scale of hundreds of billions [2] Financial Performance - The company achieved an operating revenue of 12.196 billion yuan and a net profit of -0.357 billion yuan for 2024 [2] - Operating cash flow improved significantly, reaching 1.207 billion yuan [2] - The diagnostic services segment generated revenue of 4.520 billion yuan, with the ICL segment contributing 4.173 billion yuan [3] Business Model and Strategy - The company is focusing on a "product + service + digital" model, integrating IVD products, third-party medical testing, and smart healthcare [2][3] - The company has established a three-dimensional linkage system based on the clinical needs of tertiary hospitals, with over 60% of its clients being tertiary hospitals [4] - The company has over 90 precision centers, with 53 achieving profitability and a 34% year-on-year revenue growth [4] Technological Advancements - The company is advancing smart laboratory construction and has implemented an AI algorithm-based intelligent review system, reducing manual review time by 50% and improving efficiency by 10% [3] - The company has launched a clinical research big data platform 2.0, enhancing data management across nearly 30 top-tier hospitals [6][7] - The company is actively expanding its overseas market, having opened its first overseas laboratory in Vietnam [5] Market Trends - The AI healthcare market in China has grown from 2.7 billion yuan in 2019 to 8.8 billion yuan in 2023, with a projected CAGR of 34% [6] - The company is positioned to benefit from the government's push for AI integration in healthcare, which is expected to accelerate industry transformation [6] Future Outlook - The company has initiated a new five-year strategic plan aimed at becoming the most respected leader in the Chinese diagnostic industry, focusing on integrated solutions [7] - The company aims to build an end-to-end service system covering the entire customer value chain, emphasizing the synergy of service, product, and digital capabilities [7]

Core Insights - Shanghai Jiao Tong University School of Medicine's Renji Hospital has announced its collaboration with Ant Group to develop the country's first AI-powered urology specialist system [1] - The AI system utilizes a standardized dataset of 97.6% disease spectrum cases from Renji Hospital, along with disease knowledge graphs authored by over 20 specialist doctors [1] - This initiative combines the diagnostic logic of top-tier hospitals with advanced AI technology [1]

基金管理人在一季报中表示，本基金看好医药板块确定性增长的比较优势，重点配置了创新药及其研发服务外包产业链、医疗设备及耗材、AI医疗等相关 细分赛道。 截至4月18日，招商前沿医疗保健股票A近三个月复权单位净值增长率为8.43%，位于同类可比基金33/54；近半年复权单位净值增长率为-4.05%，位于同类可 比基金42/54；近一年复权单位净值增长率为4.11%，位于同类可比基金25/54；近三年复权单位净值增长率为-35.68%，位于同类可比基金41/46。 AI基金招商前沿医疗保健股票A（011373）披露2025年一季报，第一季度基金利润7093.67万元，加权平均基金份额本期利润0.0663元。报告期内，基金净值 增长率为14.69%，截至一季度末，基金规模为5.45亿元。 该基金属于标准股票型基金，长期投资于医药医疗股票。截至4月18日，单位净值为0.473元。基金经理是李佳存，目前管理4只基金。其中，截至4月18日， 招商创新增长混合A近一年复权单位净值增长率最高，达7.71%；招商医药健康产业股票最低，为-1.74%。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为 ...